Results 241 to 250 of about 236,269 (292)

Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study. [PDF]

Blood Res
Oh S, Park SS, Lee JY, Yoon JH, Lee SE, Kim HJ, Shin SH, Jeon YW, Yahng SA, Jung J, Ahn A, Kim M, Min CK.   +12 more
europepmc   +1 more source

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma. [PDF]

Future Oncol
Gordan LN, Warner A, Heritage T, Ming A, Gupta-Werner N, Kaila S, Cortoos A.   +6 more
europepmc   +1 more source

From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management. [PDF]

Cancer Biol Med
Xu J, Fang K, Li X, Han L, Sun S, Sun T.
europepmc   +1 more source

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution. [PDF]

BMC Med
Liang JH, Wu YF, Pan SY, Du KX, Ji YL, Zhu LQ, Shen HR, Wu JZ, Yin H, Li Y, Wang L, Li JY, Xu W.   +12 more
europepmc   +1 more source

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models. [PDF]

Nat Commun
Ott CA, Purwin TJ, Chen PY, Chowdhury S, Mellor GL, Luo K, Mersky GL, Tiago M, Madden WD, Varney SD, Erkes DA, Lamar J, Capparelli C, Bollag G, Aplin AE.   +14 more
europepmc   +1 more source

Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy? [PDF]

Hematology/Oncology Clinics of North America, 2021
With the advent of highly effective novel therapies for chronic lymphocytic leukemia, conventional response assessment is not able to sensitively capture depth of response.
Othman Al-Sawaf, John F Seymour, Arnon P Kater   +2 more
exaly   +2 more sources

Minimal residual disease in cancer therapy – Small things make all the difference [PDF]

Drug Resistance Updates, 2015
Minimal residual disease (MRD) is a major hurdle in the eradication of malignant tumors. Despite the high sensitivity of various cancers to treatment, some residual cancer cells persist and lead to tumor recurrence and treatment failure.
Sohvi Blatter, Sven Rottenberg
exaly   +2 more sources

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress? [PDF]

Journal of Clinical Medicine, 2017
Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy.
Federico Mošna, Michele Gottardi, Mošna Federico   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Detection of minimal residual disease

2001
Publisher Summary Minimal residual disease (MRD) is defined as the presence of a small number of cancer cells in hematological malignancies usually below 1010 cells (that amount approximately corresponds to 1g of the total cancer cell burden in a human body).
A, Deptala, S P, Mayer
openaire   +4 more sources